Drug intelligence / Profile preview

paclitaxel + zilovertamab

Development stage: Unknown
Lead developer: Oncternal Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of paclitaxel, a taxane chemotherapy agent, and zilovertamab, a humanized monoclonal antibody targeting ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1). ROR1 is an onco-embryonic antigen expressed by malignant cells in various solid tumors, including breast cancer. Zilovertamab inhibits ROR1-signaling, which leads to activation of ERK1/2, NF-κB, and NRF2 target genes. This combination has been investigated primarily for the treatment of advanced breast cancer.

Brand names: Taxol
Other names: paclitaxel + cirmtuzumabpaclitaxel + UC-961

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)Microtubule

Beyond the preview

Go deeper on paclitaxel + zilovertamab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + zilovertamab.

Explore the full profile